Skip to content

US · BIAF · MEDICAL - DIAGNOSTICS & RESEARCH

bioAffinity Technologies, Inc. (BIAF) intrinsic value and stock valuation

$1.65as of 2026-11-21 · Mkt cap 3.33M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

bioAffinity Technologies, Inc. DCF and intrinsic value

InvestorsCraft values BIAF with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BIAF’s statements →

bioAffinity Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research San Antonio, TX 78217 bioaffinitytech.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$6.16M
20192025
Net income
-$-14.91M
20192025
Free cash flow
-$-9.39M
20192025
Total equity
$7.28M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$6.16M$9.36M$2.53M$0.00$0.00
Operating income-$-10.57M-$-8.95M-$-7.97M-$-4.01M-$-2.21M
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
EPSd-$-8.67M-$-22.6M-$-27.38M-$-54.33M-$-70.33M
Operating cash flow-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Capital expenditure-$-60K-$-80K-$-20K-$-220K-$0.00
Free cash flow-$-9.39M-$-7.34M-$-6.06M-$-4.29M-$-2.05M
Total assets$11M$6.51M$8.22M$12.2M$1.45M
Total debt$1.16M$1.5M$1.58M$250K$11.4M
Net debt-$-5.29M$400K-$-1.24M-$-11.16M$10M
Total equity$7.28M$2.6M$4.86M$11M-$-15.79M
Cash and short-term investments$6.45M$1.11M$2.82M$11.4M$1.36M
Income statement
20252024202320222021
Revenue$6.16M$9.36M$2.53M$0.00$0.00
Cost of revenue$4.73M$5.98M$1.74M$0.00$0.00
Gross profit$1.43M$3.38M$790K$0.00-$0.00
Research and development expenses$2.09M$1.78M$1.73M$1.52M$1.14M
Selling, general and administrative expenses$9.91M$9.94M$6.79M$2.48M$1.07M
Other expenses$0.00$610K$250K$10K$0.00
Operating expenses$12M$12.3M$8.77M$4.02M$2.2M
Cost and expenses$16.7M$18.3M$10.5M$4.02M$2.21M
Interest income$20K$20K$120K$50K$0.00
Interest expense$40K$90K$40K$2.53M$1M
Depreciation and amortization$500K$610K$250K$10K$0.00
Ebitda-$-14.32M-$-8.33M-$-7.63M-$-5.61M-$-5.32M
Operating income-$-10.57M-$-8.95M-$-7.97M-$-4.01M-$-2.21M
Total other income/expenses, net-$-4.29M-$-80K$60K-$-4.14M-$-4.12M
Income before tax-$-14.87M-$-9.03M-$-7.92M-$-8.15M-$-6.32M
Income tax expense$40K$10K$20K$0.00$0.00
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
Weighted average shares outstanding$1.72M$400K$290K$150K$90K
Weighted average diluted shares outstanding$1.72M$400K$290K$150K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$6.45M$1.11M$2.82M$11.4M$1.36M
Net receivables$540K$1.14M$810K$10K$0.00
Inventory$50K$30K$20K$10K$0.00
Total current assets$7.57M$2.7M$3.97M$12M$1.44M
Property, plant and equipment, net$1.26M$1.62M$1.99M$210K$0.00
Goodwill and intangible assets$2.12M$2.18M$2.24M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.4M$3.82M$4.25M$220K$20K
Total assets$11M$6.51M$8.22M$12.2M$1.45M
Accounts payable$760K$990K$600K$350K$230K
Short-term debt$380K$690K$920K$250K$11.2M
Deferred revenue$40K$20K$30K$0.00$0.00
Total current liabilities$2.91M$3.1M$2.25M$1.14M$13M
Long-term debt$780K$810K$1.12M$0.00$160K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$780K$810K$1.12M$0.00$4.2M
Capital lease obligations$740K$1.31M$1.58M$0.00$0.00
Total liabilities$3.68M$3.91M$3.37M$1.14M$17.2M
Common stock$30K$110K$70K$60K$20K
Retained earnings-$-68.55M-$-53.64M-$-44.6M-$-36.67M-$-28.51M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-4.04M
Total equity$7.28M$2.6M$4.86M$11M-$-15.79M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.16M$1.5M$1.58M$250K$11.4M
Net debt-$-5.29M$400K-$-1.24M-$-11.16M$10M
Cash flow statement
20252024202320222021
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
Depreciation and amortization$500K$610K$250K$10K$0.00
Stock-based compensation$670K$990K$750K$250K$40K
Change in working capital$590K$180K$900K$110K$630K
Accounts receivable$600K-$-330K$310K-$-10K$0.00
Inventory-$-30K-$-10K-$-10K-$-10K$0.00
Accounts payable-$-230K$380K-$-10K$110K$40K
Net cash provided by operating activities-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Investments in property, plant and equipment-$-60K-$-80K-$-20K-$-220K$0.00
Acquisitions, net$0.00$0.00-$-2.19M$0.00$0.00
Net cash used for investing activities-$-60K-$-80K-$-2.21M-$-220K$0.00
Common stock issued$15.1M$4.35M$0.00$6.03M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.7M$5.63M-$-340K$14.3M$3.33M
Net change in cash$5.34M-$-1.72M-$-8.59M$10.1M$1.28M
Cash at end of period$6.45M$1.11M$2.82M$11.4M$1.36M
Operating cash flow-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Capital expenditure-$-60K-$-80K-$-20K-$-220K-$0.00
Free cash flow-$-9.39M-$-7.34M-$-6.06M-$-4.29M-$-2.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About bioAffinity Technologies, Inc.

        As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

        CEO
        Maria Zannes
        Employees
        57
        Beta
        -1.11

        Explore

        Frequently asked questions

        What is the intrinsic value of bioAffinity Technologies, Inc. (BIAF)?

        bioAffinity Technologies, Inc. (BIAF) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BIAF undervalued?

        BIAF trades at a price of $1.65 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.